A growing number of research centres, hospitals are investigating antibody testing and blood-plasma therapy as a way to fight the new coronavirus in sick patients. People who survive an infectious disease like COVID-19 are left with antibody-rich blood plasma or convalescent plasma made to fight off the virus. Researchers are predicting convalescent plasma can be a lifeline for corona virus-infected individuals. The Ministry of Health and Family Welfare, Government of India on 27th June 2020, came out with CLINICAL MANAGEMENT PROTOCOL: COVID-19 Version 4.
A growing number of research centres, hospitals are investigating antibody testing and blood- plasma therapy as a way to fight the new coronavirus in sick patients. People who survive an infectious disease like COVID-19 are left with antibody-rich blood plasma or convalescent plasma made to fight off the virus. Researchers are predicting convalescent plasma can be a lifeline for corona virus-infected individuals. This can be transfused into newly infected patients to aid recovery. Since the beginning of the pandemic, doctors have been transfusing convalescent plasma into critically ill COVID-19 patients.
The Ministry of Health and Family Welfare, Government of India on 27th June 2020, came out with CLINICAL MANAGEMENT PROTOCOL: COVID-19 Version 4.On the basis of the protocol, CDSCO issued a notice on 1 st July, 2020 in reference of the protocol. Certain therapies in the protocol are indicated for use as investigational therapies, in which convalescent plasma by plasmapheresis has been indicated as “Off Label” in COVID-19 patients. Convalescent plasma may be considered in patients with the moderate disease who are not improving (oxygen requirement is progressively increasing) despite the use of steroids.
Dosage of convalescent plasma: The dose is variable ranging from 4 to 13 ml/kg (usually 200 ml single dose given slowly over not less than 2 hour according to the CLINICAL MANAGEMENT PROTOCOL: COVID19 Version 4
Presently, the use of these therapies is based on limited available evidence. As the COVID-19 situation evolves and more data are available, the evidence will be incorporated, and clinical protocol upgrades. Moreover, an informed and shared decision making is needed by the medical experts before prescribing this therapy.
One must obtain a drug license to launch a business selling drugs or cosmetics. No one can sell drugs or cosmetics without a drug license. The 1940 Drugs and Cosmetics Act specifies the procedure and ..
A wholesale drug license is required for manufacturing, distribution, sale, or storage of drugs. The Drugs and Cosmetics Act, 1940 outlines the requirements to obtain a manufacturing license in India...
The Central Pollution Control Board (CPCB) issued a directive alert for submission of timely annual reports by all Pollution Implementing and Beneficiary Organisations (PIBOs) to avoid any penalties. ..
Please feel free to talk to us if you have any questions. We endeavour to answer within 24 hours.